Rocket Pharmaceuticals (RCKT) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Rocket Pharmaceuticals (RCKT) over the last 10 years, with Q3 2025 value amounting to -$52.0 million.
- Rocket Pharmaceuticals' Income towards Parent Company rose 2414.68% to -$52.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$248.2 million, marking a year-over-year increase of 745.13%. This contributed to the annual value of -$266.8 million for FY2024, which is 412.81% down from last year.
- Latest data reveals that Rocket Pharmaceuticals reported Income towards Parent Company of -$52.0 million as of Q3 2025, which was up 2414.68% from -$71.1 million recorded in Q2 2025.
- Rocket Pharmaceuticals' Income towards Parent Company's 5-year high stood at -$33.8 million during Q2 2021, with a 5-year trough of -$71.9 million in Q2 2024.
- In the last 5 years, Rocket Pharmaceuticals' Income towards Parent Company had a median value of -$61.6 million in 2024 and averaged -$57.9 million.
- The largest annual percentage gain for Rocket Pharmaceuticals' Income towards Parent Company in the last 5 years was 2753.09% (2021), contrasted with its biggest fall of 7122.35% (2021).
- Over the past 5 years, Rocket Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$43.9 million in 2021, then plummeted by 55.43% to -$68.3 million in 2022, then rose by 7.86% to -$62.9 million in 2023, then rose by 2.2% to -$61.6 million in 2024, then grew by 15.5% to -$52.0 million in 2025.
- Its last three reported values are -$52.0 million in Q3 2025, -$71.1 million for Q2 2025, and -$63.5 million during Q1 2025.